Literature DB >> 12057083

Advanced larynx cancer.

Scott E Strome1, Eric C Weinman.   

Abstract

Despite advances in diagnosis and treatment, the prognosis for patients with stage III-IV laryngeal cancer is not significantly different than it was four decades ago [1]. This failure to improve survival is multifactorial and is likely linked to controversy surrounding optimal treatment regimens for a heterogeneous patient and tumor population. At the root of this controversy is a lack of randomized controlled trials that compare different therapeutic options, personal and institutional treatment philosophies, and a paucity of standardized functional and quality-of-life outcome measures for specific treatment modalities. Therapeutic decision making is further complicated by the potential use of organ preservation approaches in some patients [2**, 3*, 4**]. Clearly, quality-of-life considerations are an integral part of treatment planning and a well-informed patient is necessary to achieve an optimal result. Philosophically, it is the physician's responsibility to recommend the best treatment option and to explain the other viable treatment strategies. It is our opinion that conservation laryngeal surgery represents the mainstay of treatment for patients with advanced laryngeal carcinomas, whose tumors have characteristics amenable to these approaches and who functionally can tolerate such procedures. For those patients who would likely require a total laryngectomy or who are not suitable for surgical conservation, organ preservation should be used as a primary option in a controlled setting.

Entities:  

Mesh:

Year:  2002        PMID: 12057083     DOI: 10.1007/s11864-002-0037-9

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  34 in total

Review 1.  Treatment of advanced laryngeal cancer (T3-4).

Authors:  C H Terhaard; G J Hordijk; L A Ravasz
Journal:  Acta Otorhinolaryngol Belg       Date:  1992

2.  Radiotherapy for squamous cell carcinoma of the supraglottic larynx: an alternative to surgery.

Authors:  W M Mendenhall; J T Parsons; A A Mancuso; S P Stringer; N J Cassisi
Journal:  Head Neck       Date:  1996 Jan-Feb       Impact factor: 3.147

3.  Cricohyoidoepiglottopexy for glottic carcinoma with fixation or impaired motion of the true vocal cord: 5-year oncologic results with 112 patients.

Authors:  D Chevalier; O Laccourreye; D Brasnu; H Laccourreye; J J Piquet
Journal:  Ann Otol Rhinol Laryngol       Date:  1997-05       Impact factor: 1.547

4.  T4 laryngeal carcinoma: radiotherapy alone with surgery reserved for salvage.

Authors:  J T Parsons; W M Mendenhall; S P Stringer; N J Cassisi
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-02-01       Impact factor: 7.038

5.  Epidermoid carcinoma of the supraglottic larynx. Role of neck dissection in initial surgical treatment.

Authors:  J P Shah; H R Tollefsen
Journal:  Am J Surg       Date:  1974-10       Impact factor: 2.565

6.  A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx.

Authors:  K T Robbins; J Fontanesi; F S Wong; D Vicario; S Seagren; P Kumar; R Weisman; P Pellitteri; J R Thomas; P Flick; R Palmer; A Weir; C Kerber; T Murry; R Ferguson; G Los; L Orloff; S B Howell
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1996-08

Review 7.  T3-4 squamous cell carcinoma of the larynx treated with radiation therapy alone.

Authors:  W M Mendenhall
Journal:  Semin Radiat Oncol       Date:  1998-10       Impact factor: 5.934

8.  Transglottic carcinoma.

Authors:  B Mittal; J E Marks; J H Ogura
Journal:  Cancer       Date:  1984-01-01       Impact factor: 6.860

9.  Clinical vs histopathologic staging in laryngeal cancer.

Authors:  H R Pillsbury; J A Kirchner
Journal:  Arch Otolaryngol       Date:  1979-03

Review 10.  Advances in multimodality therapy for laryngeal cancer.

Authors:  J F Carew; J P Shah
Journal:  CA Cancer J Clin       Date:  1998 Jul-Aug       Impact factor: 508.702

View more
  2 in total

1.  Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.

Authors:  Alan A Z Alexander; Amudhan Maniar; Jean-Saville Cummings; Andrew M Hebbeler; Dan H Schulze; Brian R Gastman; C David Pauza; Scott E Strome; Andrei I Chapoval
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

2.  Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.

Authors:  Alexander Gelbard; Charlie T Garnett; Scott I Abrams; Vyomesh Patel; J Silvio Gutkind; Claudia Palena; Kwong-Yok Tsang; Jeffrey Schlom; James W Hodge
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.